Augmedix, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Revenues
Cost of revenues
Gross profit
Operating expenses:
General and administrative
Sales and marketing
Research and development
Total operating expenses
Loss from operations
Other income (expenses):
Interest expense
Interest income
Loss on debt extinguishment
Forgiveness of PPP loan
Change in fair value of warrant liability
Other
Total other income (expenses)
Loss before income taxes
Income tax expense
Net loss
Other comprehensive loss:
Foreign currency translation adjustment
Total comprehensive loss
Net loss per share of common stock, basic and diluted (in Dollars per share)
Weighted average shares of common stock outstanding, basic and diluted (in Shares)
Total comprehensive loss
Net loss per share of common stock, basic (in dollars per share)
Net loss per share of common stock, diluted (in dollars per share)
Weighted average shares of common stock outstanding, basic (in shares)
Weighted average shares of common stock outstanding, diluted (in shares)

Comments